A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

NCT04665063 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Auto CAR-T
DRUG: Cyclophosphamide,Fludarabine
PROCEDURE: Leukapheresis

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]